Literature DB >> 24729833

Molecular imaging of macrophage enzyme activity in cardiac inflammation.

Muhammad Ali1, Benjamin Pulli1, John W Chen2.   

Abstract

Molecular imaging is highly advantageous as various insidious inflammatory events can be imaged in a serial and quantitative fashion. Combined with the conventional imaging modalities like computed tomography (CT), magnetic resonance (MR) and nuclear imaging, it helps us resolve the extent of ongoing pathology, quantify inflammation and predict outcome. Macrophages are increasingly gaining importance as an imaging biomarker in inflammatory cardiovascular diseases. Macrophages, recruited to the site of injury, internalize necrotic or foreign material. Along with phagocytosis, activated macrophages release proteolytic enzymes like matrix metalloproteinases (MMPs) and cathepsins into the extracellular environment. Pro-inflammatory monocytes and macrophages also induce tissue oxidative damage through the inflammatory enzyme myeloperoxidase (MPO). In this review we will highlight recent advances in molecular macrophage imaging. Particular stress will be given to macrophage functional and enzymatic activity imaging which targets phagocytosis, proteolysis and myeloperoxidase activity imaging.

Entities:  

Keywords:  Molecular imaging; atherosclerosis; cardiovascular; enzyme activity; inflammation; macrophage; myeloperoxidase; myocardial infarction; phagocytes; protease; transplant rejection

Year:  2014        PMID: 24729833      PMCID: PMC3979571          DOI: 10.1007/s12410-014-9258-0

Source DB:  PubMed          Journal:  Curr Cardiovasc Imaging Rep        ISSN: 1941-9074


  92 in total

1.  What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro.

Authors:  Mikako Ogawa; Satoki Nakamura; Yuriko Saito; Mutsumi Kosugi; Yasuhiro Magata
Journal:  J Nucl Med       Date:  2011-11-29       Impact factor: 10.057

2.  Monocyte and/or macrophage infiltration of heart after myocardial infarction: MR imaging by using T1-shortening liposomes.

Authors:  Nivedita K Naresh; Yaqin Xu; Alexander L Klibanov; Moriel H Vandsburger; Craig H Meyer; Jonathan Leor; Christopher M Kramer; Brent A French; Frederick H Epstein
Journal:  Radiology       Date:  2012-06-21       Impact factor: 11.105

3.  Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages.

Authors:  Rikin A Trivedi; Chinthake Mallawarachi; Jean-Marie U-King-Im; Martin J Graves; Jo Horsley; Martin J Goddard; Andrew Brown; Liqun Wang; Peter J Kirkpatrick; John Brown; Jonathan H Gillard
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-04-20       Impact factor: 8.311

Review 4.  Multimodality cardiovascular molecular imaging, part I.

Authors:  Albert J Sinusas; Frank Bengel; Matthias Nahrendorf; Frederick H Epstein; Joseph C Wu; Flordeliza S Villanueva; Zahi A Fayad; Robert J Gropler
Journal:  Circ Cardiovasc Imaging       Date:  2008-11       Impact factor: 7.792

Review 5.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

6.  (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials.

Authors:  James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Ash Rafique; Michael Farkouh; Valentin Fuster; Zahi A Fayad
Journal:  J Am Coll Cardiol       Date:  2007-08-13       Impact factor: 24.094

Review 7.  Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease.

Authors:  Betty S van der Veen; Menno P J de Winther; Peter Heeringa
Journal:  Antioxid Redox Signal       Date:  2009-11       Impact factor: 8.401

8.  Inflammation-specific T1 imaging using anti-intercellular adhesion molecule 1 antibody-conjugated gadolinium diethylenetriaminepentaacetic acid.

Authors:  Kyu-Sil Choi; Sun-Hee Kim; Quan-Yu Cai; Soo-Yeon Kim; Hyang-Ok Kim; Hye-Jin Lee; Eun-A Kim; Seong-Eon Yoon; Ki-Jung Yun; Kwon-Ha Yoon
Journal:  Mol Imaging       Date:  2007 Mar-Apr       Impact factor: 4.488

9.  Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury.

Authors:  Matthias Nahrendorf; David Sosnovik; John W Chen; Peter Panizzi; Jose-Luiz Figueiredo; Elena Aikawa; Peter Libby; Filip K Swirski; Ralph Weissleder
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

10.  Noninvasive evaluation of cardiac allograft rejection by cellular and functional cardiac magnetic resonance.

Authors:  Yijen L Wu; Qing Ye; Kazuya Sato; Lesley M Foley; T Kevin Hitchens; Chien Ho
Journal:  JACC Cardiovasc Imaging       Date:  2009-06
View more
  4 in total

1.  mTORC1 signaling is crucial for regulatory T cells to suppress macrophage-mediated inflammatory response after acute myocardial infarction.

Authors:  Keping Yang; Yunfeng Zhang; Chenhong Xu; Xin Li; Dazhu Li
Journal:  Immunol Cell Biol       Date:  2015-10-06       Impact factor: 5.126

Review 2.  Recent progress in the imaging detection of enzyme activities in vivo.

Authors:  Chunjie Yang; Qian Wang; Wu Ding
Journal:  RSC Adv       Date:  2019-08-13       Impact factor: 4.036

Review 3.  Searching for novel PET radiotracers: imaging cardiac perfusion, metabolism and inflammation.

Authors:  Caitlund Q Davidson; Christopher P Phenix; T C Tai; Neelam Khaper; Simon J Lees
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-06-05

4.  Kolaviron attenuated arsenic acid induced-cardiorenal dysfunction via regulation of ROS, C-reactive proteins (CRP), cardiac troponin I (CTnI) and BCL2.

Authors:  Ademola Adetokunbo Oyagbemi; Temidayo Olutayo Omobowale; Ebunoluwa Racheal Asenuga; John Olusoji Abiola; Adeolu Alex Adedapo; Momoh Audu Yakubu
Journal:  J Tradit Complement Med       Date:  2017-12-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.